The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model

Kentaro Miyake; Takashi Higuchi; Hiromichi Oshiro; Zhiying Zhang; Norihiko Sugisawa; Jun Ho Park; Sahar Razmjooei; Yuki Katsuya; Maryam Barangi; Yunfeng Li; Scott D. Nelson; Takashi Murakami; Yuki Homma; Yukihiko Hiroshima; Ryusei Matsuyama; Michael Bouvet; Sant P. Chawla; Shree Ram Singh; Itaru Endo; Robert M. Hoffman

doi:10.1016/j.biopha.2019.109093

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model

Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Norihiko Sugisawa, Jun Ho Park, Sahar Razmjooei, Yuki Katsuya, Maryam Barangi, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yuki Homma, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouvet, Sant P. Chawla, Shree Ram Singh, Itaru Endo, Robert M. Hoffman

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Liposarcoma (LS) is a chemotherapy-resistant disease. The aim of the present study was to find precise therapy for a recurrent dedifferentiated liposarcoma (DDLS) in a patient-derived orthotopic xenograft (PDOX) model. The DDLS PDOX models were established orthotopically in the right inguinal area of nude mice. The DDLS PDOX models were randomized into five groups: untreated; doxorubicin (DOX); gemcitabine (GEM) combined with docetaxel (DOC); pazopanib (PAZ); and yondelis (YON). On day 15, all mice were sacrificed. Measurement of tumor volume and body weight were done two times a week. The DDLS PDOX was resistant to DOX (P > 0.184). YON suppressed tumor growth significantly compared to control group (P < 0.027). However, only GEM combined with DOC arrested the tumor growth (P < 0.001). These findings suggest that GEM combined with DOC has clinical potential for this and possibly other DDLS patients.

Original language	English
Article number	109093
Journal	Biomedicine and Pharmacotherapy
Volume	117
DOIs	https://doi.org/10.1016/j.biopha.2019.109093
Publication status	Published - 2019 Sept
Externally published	Yes

Keywords

Docetaxel
Gemcitabine
Liposarcoma
Nude mice
PDOX
Patient-derived orthotopic xenograft

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.biopha.2019.109093

Cite this

Miyake, K., Higuchi, T., Oshiro, H., Zhang, Z., Sugisawa, N., Park, J. H., Razmjooei, S., Katsuya, Y., Barangi, M., Li, Y., Nelson, S. D., Murakami, T., Homma, Y., Hiroshima, Y., Matsuyama, R., Bouvet, M., Chawla, S. P., Singh, S. R., Endo, I., & Hoffman, R. M. (2019). The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. Biomedicine and Pharmacotherapy, 117, [109093]. https://doi.org/10.1016/j.biopha.2019.109093

Miyake, K, Higuchi, T, Oshiro, H, Zhang, Z, Sugisawa, N, Park, JH, Razmjooei, S, Katsuya, Y, Barangi, M, Li, Y, Nelson, SD, Murakami, T, Homma, Y, Hiroshima, Y, Matsuyama, R, Bouvet, M, Chawla, SP, Singh, SR, Endo, I & Hoffman, RM 2019, 'The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model', Biomedicine and Pharmacotherapy, vol. 117, 109093. https://doi.org/10.1016/j.biopha.2019.109093

@article{4c398a8c7877481794ef4f2efa19a3c4,

title = "The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model",

abstract = "Liposarcoma (LS) is a chemotherapy-resistant disease. The aim of the present study was to find precise therapy for a recurrent dedifferentiated liposarcoma (DDLS) in a patient-derived orthotopic xenograft (PDOX) model. The DDLS PDOX models were established orthotopically in the right inguinal area of nude mice. The DDLS PDOX models were randomized into five groups: untreated; doxorubicin (DOX); gemcitabine (GEM) combined with docetaxel (DOC); pazopanib (PAZ); and yondelis (YON). On day 15, all mice were sacrificed. Measurement of tumor volume and body weight were done two times a week. The DDLS PDOX was resistant to DOX (P > 0.184). YON suppressed tumor growth significantly compared to control group (P < 0.027). However, only GEM combined with DOC arrested the tumor growth (P < 0.001). These findings suggest that GEM combined with DOC has clinical potential for this and possibly other DDLS patients.",

keywords = "Docetaxel, Gemcitabine, Liposarcoma, Nude mice, PDOX, Patient-derived orthotopic xenograft",

author = "Kentaro Miyake and Takashi Higuchi and Hiromichi Oshiro and Zhiying Zhang and Norihiko Sugisawa and Park, {Jun Ho} and Sahar Razmjooei and Yuki Katsuya and Maryam Barangi and Yunfeng Li and Nelson, {Scott D.} and Takashi Murakami and Yuki Homma and Yukihiko Hiroshima and Ryusei Matsuyama and Michael Bouvet and Chawla, {Sant P.} and Singh, {Shree Ram} and Itaru Endo and Hoffman, {Robert M.}",

note = "Funding Information: This work was supported in part by a Yokohama City University research grant “KAMOME Project” , which had no role in the design, execution, interpretation, or writing of the study. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = sep,

doi = "10.1016/j.biopha.2019.109093",

language = "English",

volume = "117",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

}

TY - JOUR

T1 - The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model

AU - Miyake, Kentaro

AU - Higuchi, Takashi

AU - Oshiro, Hiromichi

AU - Zhang, Zhiying

AU - Sugisawa, Norihiko

AU - Park, Jun Ho

AU - Razmjooei, Sahar

AU - Katsuya, Yuki

AU - Barangi, Maryam

AU - Li, Yunfeng

AU - Nelson, Scott D.

AU - Murakami, Takashi

AU - Homma, Yuki

AU - Hiroshima, Yukihiko

AU - Matsuyama, Ryusei

AU - Bouvet, Michael

AU - Chawla, Sant P.

AU - Singh, Shree Ram

AU - Endo, Itaru

AU - Hoffman, Robert M.

N1 - Funding Information: This work was supported in part by a Yokohama City University research grant “KAMOME Project” , which had no role in the design, execution, interpretation, or writing of the study. Publisher Copyright: © 2019 The Authors

PY - 2019/9

Y1 - 2019/9

N2 - Liposarcoma (LS) is a chemotherapy-resistant disease. The aim of the present study was to find precise therapy for a recurrent dedifferentiated liposarcoma (DDLS) in a patient-derived orthotopic xenograft (PDOX) model. The DDLS PDOX models were established orthotopically in the right inguinal area of nude mice. The DDLS PDOX models were randomized into five groups: untreated; doxorubicin (DOX); gemcitabine (GEM) combined with docetaxel (DOC); pazopanib (PAZ); and yondelis (YON). On day 15, all mice were sacrificed. Measurement of tumor volume and body weight were done two times a week. The DDLS PDOX was resistant to DOX (P > 0.184). YON suppressed tumor growth significantly compared to control group (P < 0.027). However, only GEM combined with DOC arrested the tumor growth (P < 0.001). These findings suggest that GEM combined with DOC has clinical potential for this and possibly other DDLS patients.

AB - Liposarcoma (LS) is a chemotherapy-resistant disease. The aim of the present study was to find precise therapy for a recurrent dedifferentiated liposarcoma (DDLS) in a patient-derived orthotopic xenograft (PDOX) model. The DDLS PDOX models were established orthotopically in the right inguinal area of nude mice. The DDLS PDOX models were randomized into five groups: untreated; doxorubicin (DOX); gemcitabine (GEM) combined with docetaxel (DOC); pazopanib (PAZ); and yondelis (YON). On day 15, all mice were sacrificed. Measurement of tumor volume and body weight were done two times a week. The DDLS PDOX was resistant to DOX (P > 0.184). YON suppressed tumor growth significantly compared to control group (P < 0.027). However, only GEM combined with DOC arrested the tumor growth (P < 0.001). These findings suggest that GEM combined with DOC has clinical potential for this and possibly other DDLS patients.

KW - Docetaxel

KW - Gemcitabine

KW - Liposarcoma

KW - Nude mice

KW - PDOX

KW - Patient-derived orthotopic xenograft

UR - http://www.scopus.com/inward/record.url?scp=85067083381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067083381&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2019.109093

DO - 10.1016/j.biopha.2019.109093

M3 - Article

C2 - 31200257

AN - SCOPUS:85067083381

SN - 0753-3322

VL - 117

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 109093

ER -

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this